Trade

with

NxStage Medical Inc
(NASDAQ: NXTM)
AdChoices
13.61
+0.05
+0.37%
After Hours :
13.61
0.00
0.00%

Open

13.76

Previous Close

13.56

Volume (Avg)

313.54k (275.46k)

Day's Range

13.51-13.77

52Wk Range

8.77-15.50

Market Cap.

841.46M

Dividend Rate ( Yield )

-

Beta

0.70

Shares Outstanding

61.83M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Medical Instruments & Supplies
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 263.43M

    • Net Income

    • -18.56M

    • Market Cap.

    • 841.46M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -7.98

    • PEG (Price/Earnings Growth) Ratio

    • 2.39

    • Beta

    • 0.70

    • Forward P/E

    • 48.54

    • Price/Sales

    • 2.94

    • Price/Book Value

    • 4.43

    • Price/Cash flow

    • -55.87

      • EBITDA

      • 6.65M

      • Return on Capital %

      • -7.21

      • Return on Equity %

      • -11.67

      • Return on Assets %

      • -7.21

      • Book Value/Share

      • 3.07

      • Shares Outstanding

      • 61.83M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 22.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.46

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 13.20

          • 10.42

          • Net Income

            YTD/YTD (last year)

          • -

          • -15.59

          • Net Income

            Q/Q (last year)

          • -

          • -8.93

          • Sales (Revenue)

            5-Year Annual Average

          • 15.39

          • 12.51

          • Net Income

            5-Year Annual Average

          • -

          • 4.16

          • Dividends

            5-Year Annual Average

          • -

          • 0.97

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 38.88

            • 52.83

            • Pre-Tax Margin

            • -7.55

            • 15.96

            • Net Profit Margin

            • -7.98

            • 12.40

            • Average Gross Margin

              5-Year Annual Average

            • 34.00

            • 52.66

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -13.70

            • 18.40

            • Average Net Profit Margin

              5-Year Annual Average

            • -14.00

            • 93.46B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.01

              • 0.62

              • Current Ratio

              • 3.09

              • 1.97

              • Quick Ratio

              • 2.04

              • 1.16

              • Interest Coverage

              • -29.31

              • 10.47

              • Leverage Ratio

              • 1.65

              • 2.38

              • Book Value/Share

              • 3.07

              • 12.11

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -36.23

                • 35.09

                • P/E Ratio 5-Year High

                • -73.54

                • 279.76

                • P/E Ratio 5-Year Low

                • -14.59

                • 148.87

                • Price/Sales Ratio

                • 2.89

                • 3.22

                • Price/Book Value

                • 4.36

                • 4.03

                • Price/Cash Flow Ratio

                • -55.87

                • 16.69

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -11.67

                    (-19.90)

                  • 17.93

                    (21.42)

                  • Return on Assets %

                    (5-Year Average)

                  • -7.21

                    (-10.60)

                  • 7.35

                    (9.50)

                  • Return on Capital %

                    (5-Year Average)

                  • -11.26

                    (-18.10)

                  • 10.24

                    (13.59)

                  • Income/Employee

                  • -

                  • 25.65k

                  • Inventory Turnover

                  • 4.18

                  • 2.66

                  • Asset Turnover

                  • 0.90

                  • 0.59

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -17.80M
                  Operating Margin
                  -6.76
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -55.87
                  Ownership

                  Institutional Ownership

                  91.89%

                  Top 10 Institutions

                  54.41%

                  Mutual Fund Ownership

                  30.17%

                  Float

                  98.05%

                  5% / Insider Ownership

                  8.77%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Health Care Portfolio

                  •  

                    1,700,000

                  • 0.00

                  • 2.75

                  • Broadview Opportunity Fund

                  •  

                    1,466,525

                  • 0.00

                  • 2.38

                  • Fidelity® Select Medical Equip & Systems

                  •  

                    1,160,000

                  • 0.00

                  • 1.88

                  • iShares Russell 2000 (AU)

                  •  

                    973,263

                  • 3.56

                  • 1.63

                  • Vanguard Small Cap Index

                  •  

                    967,588

                  • 0.42

                  • 1.57

                  • Vanguard Total Stock Mkt Idx

                  •  

                    899,781

                  • 0.50

                  • 1.46

                  • William Blair Small Cap Growth Fund

                  •  

                    754,062

                  • 0.00

                  • 1.22

                  • CI Global Health Sciences Corporate Cl

                  •  

                    666,300

                  • 0.00

                  • 1.09

                  • Vanguard Small Cap Growth Index Fund

                  •  

                    653,136

                  • -1.48

                  • 1.06

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Deerfield Management Co

                  •  

                    4,899,721

                  • +28.90%

                  • 7.95

                  • Gilder Gagnon Howe & CO LLC

                  •  

                    4,244,971

                  • -1.05%

                  • 6.89

                  • Fidelity Management and Research Company

                  •  

                    4,097,471

                  • +54.88%

                  • 6.65

                  • Oracle Investment Management Inc

                  •  

                    3,723,407

                  • +3.45%

                  • 6.04

                  • Blair William & Co

                  •  

                    3,685,063

                  • -8.79%

                  • 5.98

                  • Vanguard Group, Inc.

                  •  

                    3,375,907

                  • -0.56%

                  • 5.48

                  • MUBADALA DEVELOPMENT CO PJSC

                  •  

                    3,138,083

                  • +4.27%

                  • 5.11

                  • Cortina Asset Management LLC

                  •  

                    2,922,498

                  • -1.87%

                  • 4.74

                  • BlackRock Fund Advisors

                  •  

                    1,714,184

                  • +0.09%

                  • 2.78

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Medical Instruments & Supplies

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  NxStage Medical, Inc., was incorporated in Delaware in 1998 under the name QB Medical, Inc., and later changed its name to NxStage Medical, Inc. NxStage is a medical device company that develops, manufactures and markets products for...more the treatment of kidney failure, fluid overload and related blood treatments and procedures. Its main product, the NxStage System One was designed to satisfy an unmet clinical need for a system that could deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller, portable, easy-to-use form that could be used by healthcare professionals and trained lay users alike in a number of settings, including patient homes, as well as more traditional care settings such as hospitals and dialysis clinics. Given its design, t...morehe System One is particularly well-suited for home hemodialysis and a range of dialysis therapies including more frequent, or ‘daily,’ dialysis. The System One is cleared by the United States Food and Drug Administration for home hemodialysis as well as hospital and clinic-based dialysis. It also sells needles and blood tubing sets mainly to dialysis clinics for the treatment of End Stage Renal Disease, or ESRD. The Company has two reporting segments, System One and In-Center. It distributes its products in three markets: the home, critical care and in-center. Within the System One segment, the Company sells and rentals System One and PureFlow SL equipment and sells disposable products in the home and critical care markets. The home market consists of dialysis centers that provide treatment options for patients that have ESRD, while the critical care market consists of hospitals or facilities that treat patients that have suddenly, and possibly temporarily, lost kidney function. The company sells essentially the same System One cyclers and disposables within each market and some of the company’s largest customers in the home market provide outsourced renal dialysis services to hospitals in the critical care market to which the company sells System One cyclers and disposables. Sales of products to both markets are made through dedicated sales forces and products are distributed directly to the customer. Within the In-Center segment, the Company sells blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis. Nearly all In-Center products are sold through national distributors. The Company competes with Fresenius, Gambro, Nipro, Baxter International, Inc., or Baxter, JMS and others. The Company is subject to government regulation in the countries in which it conducts business. In the foreign countries in which the Company market and sell its products, it is subject to local regulations affecting, among other things, design and product standards, packaging and labeling and promotion requirements.lessless

                  Key People

                  Jeffrey H. Burbank

                  CEO/Director

                  Robert G. Funari

                  Director/Chairman of the Board

                  Matthew W. Towse

                  Senior VP/CFO/Treasurer

                  Kevin Hershberger

                  Vice President/Chief Accounting Officer/Controller

                  Daniel A. Giannini

                  Director

                  • NxStage Medical Inc

                  • 350 Merrimack Street

                  • Lawrence, MA 01843

                  • USA.Map

                  • Phone: +1 978 687-4700

                  • Fax: -

                  • nxstage.com

                  Incorporated

                  1998

                  Employees

                  3,200

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: